Primary Graft Dysfunction: Definition, Risk Factors, Short- and Long-Term Outcomes

James C Lee; Jason D. Christie; Shaf Keshavjee

doi:10.1055/s-0030-1249111

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2010; 31(2): 161-171
DOI: 10.1055/s-0030-1249111

Primary Graft Dysfunction: Definition, Risk Factors, Short- and Long-Term Outcomes

James C. Lee¹ , Jason D. Christie¹ ^, ² , Shaf Keshavjee³

¹Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
²Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
³Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

Abstract

ABSTRACT

Primary graft dysfunction (PGD) is a form of early lung graft dysfunction that is a major cause of early morbidity and mortality following lung transplantation. Survivors of PGD have decreased long-term lung function and an increased risk of developing bronchiolitis obliterans syndrome (BOS), a manifestation of chronic graft dysfunction. This article reviews the current definition, contributing factors, and guidelines for grading clinical PGD, as well as controversies surrounding them. The current literature examining clinical risk factors for PGD is summarized, as are studies exploring molecular and biochemical markers for PGD prediction and severity. Studies examining the short- and long-term effects of PGD on lung transplant outcomes are reviewed. Lastly, we highlight the emerging concepts in lung transplantation that will potentially impact PGD incidence and outcomes.

KEYWORDS

Primary graft dysfunction - ischemia-reperfusion injury - lung transplantation

Volltext

Referenzen

REFERENCES

1 Christie J D, Bavaria J E, Palevsky H I et al.. Primary graft failure following lung transplantation. Chest. 1998; 114 51-60
2 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg. 2000; 69 1681-1685
3 Christie J D, Kotloff R M, Pochettino A et al.. Clinical risk factors for primary graft failure following lung transplantation. Chest. 2003; 124 1232-1241
4 Arcasoy S M, Kotloff R M. Lung transplantation. N Engl J Med. 1999; 340 1081-1091
5 Christie J D, Van Raemdonck D, de Perrot M ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant. 2005; 24 1451-1453
6 Arcasoy S M, Fisher A, Hachem R R, Scavuzzo M, Ware L B. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant. 2005; 24 1483-1488
7 Christie J D, Kotloff R M, Ahya V N et al.. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005; 171 1312-1316
8 Christie J D, Carby M, Bag R, Corris P, Hertz M, Weill D. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005; 24 1454-1459
9 Daud S A, Yusen R D, Meyers B F et al.. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007; 175 507-513
10 Barr M L, Kawut S M, Whelan T P ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, IV: Recipient-related risk factors and markers. J Heart Lung Transplant. 2005; 24 1468-1482
11 Whitson B A, Nath D S, Johnson A C et al.. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006; 131 73-80
12 Prekker M E, Nath D S, Walker A R et al.. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant. 2006; 25 371-378
13 Prekker M E, Herrington C S, Hertz M I, Radosevich D M, Dahlberg P S. Early trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest. 2007; 132 991-997
14 Oto T, Levvey B J, Snell G I. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant. 2007; 26 431-436
15 Christie J, Keshavjee S, Orens J ISHLT Working Group on PGD et al. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant. 2008; 27 138
16 Oto T, Griffiths A P, Levvey B J, Pilcher D V, Williams T J, Snell G I. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg. 2006; 132 140-147
17 de Perrot M, Liu M, Waddell T K, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003; 167 490-511
18 Carter Y M, Gelman A E, Kreisel D. Pathogenesis, management, and consequences of primary graft dysfunction. Semin Thorac Cardiovasc Surg. 2008; 20 165-172
19 Frank M M. Complement in the pathophysiology of human disease. N Engl J Med. 1987; 316 1525-1530
20 de Perrot M, Bonser R S, Dark J ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, III: Donor-related risk factors and markers. J Heart Lung Transplant. 2005; 24 1460-1467
21 Lee J C, Christie J D. Primary graft dysfunction. Proc Am Thorac Soc. 2009; 6 39-46
22 Meyer D M, Bennett L E, Novick R J, Hosenpud J D. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest. 2000; 118 1255-1262
23 Oto T, Griffiths A P, Levvey B et al.. A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation. 2004; 78 599-606
24 Lee J CKC, Hadjiliadis D, Aahya V N et al.. Risk factors for early vs late primary graft dysfunction [abstract]. Am J Respir Crit Care Med. 2008; 177 A396
25 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg. 2000; 69 1681-1685
26 Thabut G, Vinatier I, Stern J B et al.. Primary graft failure following lung transplantation: predictive factors of mortality. Chest. 2002; 121 1876-1882
27 Covarrubias M, Ware L B, Kawut S M Lung Transplant Outcomes Group et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant. 2007; 7 2573-2578
28 Kawut S M, Okun J, Shimbo D et al.. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. Chest. 2009; 136 237-244
29 Lee J C, Kuntz C, Kawut S M et al.. Clinical risk factors for the development of primary graft dysfunction [abstract]. J Heart Lung Transplant. 2008; 27 S67-S68
30 Cassivi S D, Meyers B F, Battafarano R J et al.. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg. 2002; 74 1663-1669 discussion 1669-1670
31 Fiser S M, Kron I L, McLendon Long S, Kaza A K, Kern J A, Tribble C G. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant. 2001; 20 631-636
32 Hadjiliadis D, Chaparro C, Reinsmoen N L et al.. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant. 2005; 24(7, Suppl) S249-S254
33 Yoshida S, Haque A, Mizobuchi T et al.. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant. 2006; 6 724-735
34 Bobadilla J L, Love R B, Jankowska-Gan E et al.. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med. 2008; 177 660-668
35 Sommers K E, Griffith B P, Hardesty R L, Keenan R J. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg. 1996; 62 784-790
36 Szeto W Y, Kreisel D, Karakousis G C et al.. Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. J Thorac Cardiovasc Surg. 2002; 124 241-249
37 Wang Y, Kurichi J E, Blumenthal N P et al.. Multiple variables affecting blood usage in lung transplantation. J Heart Lung Transplant. 2006; 25 533-538
38 Webert K E, Blajchman M A. Transfusion-related acute lung injury. Transfus Med Rev. 2003; 17 252-262
39 Christie J D, Shah C V, Kawut S M Lung Transplant Outcomes Group et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med. 2009; 180 1010-1015
40 dos Santos C C, Okutani D, Hu P et al.. Differential gene profiling in acute lung injury identifies injury-specific gene expression. Crit Care Med. 2008; 36 855-865
41 Li J, Nie J, Chen G et al.. Gene expression profile of pulmonary tissues in different phases of lung ischemia-reperfusion injury in rats. J Huazhong Univ Sci Technolog Med Sci. 2007; 27 564-570
42 Ray M, Dharmarajan S, Freudenberg J, Zhang W, Patterson G A. Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation. Am J Transplant. 2007; 7 2396-2405
43 Anraku M, Cameron M J, Waddell T K et al.. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant. 2008; 8 2140-2148
44 Kaneda H, Waddell T K, de Perrot M et al.. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant. 2006; 6 544-551
45 Calfee C S, Budev M M, Matthay M A et al.. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant. 2007; 26 675-680
46 Kawut S M, Okun J, Shimbo D Lung Transplant Outcomes Group et al. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest. 2009; 136 237-244
47 Hoffman S A, Wang L, Shah C V Lung Transplant Outcomes Group et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009; 9 389-396
48 Fisher A J, Donnelly S C, Hirani N et al.. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med. 2001; 163 259-265
49 De Perrot M, Sekine Y, Fischer S et al.. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med. 2002; 165 211-215
50 Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, Aharinejad S. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant. 2007; 7 700-706
51 Christie J D, Robinson N, Ware L B et al.. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med. 2007; 175 69-74
52 Justice A C, Covinsky K E, Berlin J A. Assessing the generalizability of prognostic information. Ann Intern Med. 1999; 130 515-524
53 Khan S U, Salloum J, O'Donovan P B et al.. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest. 1999; 116 187-194
54 Burton C M, Iversen M, Milman N et al.. Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg. 2007; 31 75-82
55 Whitson B A, Prekker M E, Herrington C S et al.. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007; 26 1004-1011
56 Christie J D, Sager J S, Kimmel S E et al.. Impact of primary graft failure on outcomes following lung transplantation. Chest. 2005; 127 161-165
57 Fiser S M, Tribble C G, Long S M et al.. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg. 2002; 73 1041-1047 discussion 1047-1048
58 Fisher A J, Wardle J, Dark J H, Corris P A. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant. 2002; 21 1206-1212
59 Girgis R E, Tu I, Berry G J et al.. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996; 15 1200-1208
60 Hachem R R, Khalifah A P, Chakinala M M et al.. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005; 80 1406-1413
61 Khalifah A P, Hachem R R, Chakinala M M et al.. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant. 2005; 5 2022-2030
62 Huang H J, Yusen R D, Meyers B F et al.. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant. 2008; 8 2454-2462
63 Halloran P F, Homik J, Goes N et al.. The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc. 1997; 29 79-81
64 Bharat A, Kuo E, Steward N et al.. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg. 2008; 86 189-195 discussion 196-197
65 Burlingham W J, Love R B, Jankowska-Gan E et al.. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007; 117 3498-3506
66 Hornby K, Ross H, Keshavjee S, Rao V, Shemie S D. Non-utilization of hearts and lungs after consent for donation: a Canadian multicentre study. Can J Anaesth. 2006; 53 831-837
67 Ware L B, Wang Y, Fang X et al.. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet. 2002; 360 619-620
68 Oto T. Lung transplantation from donation after cardiac death (non-heart-beating) donors. Gen Thorac Cardiovasc Surg. 2008; 56 533-538
69 Neyrinck A P, Van De Wauwer C, Geudens N et al.. Comparative study of donor lung injury in heart-beating versus non-heart-beating donors. Eur J Cardiothorac Surg. 2006; 30 628-636
70 De Vleeschauwer S, Van Raemdonck D, Vanaudenaerde B et al.. Early outcome after lung transplantation from non-heart-beating donors is comparable to heart-beating donors. J Heart Lung Transplant. 2009; 28 380-387
71 Inci I, Zhai W, Arni S et al.. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors. J Heart Lung Transplant. 2007; 26 1054-1060
72 Loehe F, Preissler G, Annecke T, Bittmann I, Jauch K W, Messmer K. Continuous infusion of nitroglycerin improves pulmonary graft function of non-heart-beating donor lungs. Transplantation. 2004; 77 1803-1808
73 Rega F R, Wuyts W A, Vanaudenaerde B M et al.. Nebulized N-acetyl cysteine protects the pulmonary graft inside the non-heart-beating donor. J Heart Lung Transplant. 2005; 24 1369-1377
74 Cypel M, Yeung J C, Hirayama S et al.. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008; 27 1319-1325
75 Cypel M YJ, Liu M, Chen F et al.. Normothermic human ex vivo lung perfusion (EVLP) for improved assessment of extended criteria donor lungs for transplantation [abstract]. J Heart Lung Transplant. 2009; 28 S126

James C LeeM.D.

Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine

826 West Gates Bldg., 3400 Spruce St., Philadelphia, PA 19104

eMail: james.lee@uphs.upenn.edu